뒤로
Celcuity Inc(CELC) 가격
CELC 주가 차트
CELC 수입
Celcuity Inc
$105.39
-1.46%
$-1.56
종가: Jan 20, 16:00:00 GMT-5
$106.5
1.05%
$1.1
애프터마켓: Jan 20, 20:00:00 GMT-5
주요 통계
이전 종가
$106.96
시가
$104
일일 범위
$103 - $108.03
52주 범위
$7.57 - $116.44
거래량
720.0K
평균 거래량
988.8K
EPS(TTM)
-3.67
배당수익률
--
시가총액
$4.9B
CELC란 무엇인가요?
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 87 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.